Contrasting TapImmune (NASDAQ:MRKR) and Reata Pharmaceuticals (NASDAQ:RETA)

TapImmune (NASDAQ:MRKR) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Analyst Ratings

This is a summary of current ratings for TapImmune and Reata Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TapImmune 0 0 5 1 3.17
Reata Pharmaceuticals 0 0 5 0 3.00

TapImmune currently has a consensus price target of $10.90, suggesting a potential upside of 72.23%. Reata Pharmaceuticals has a consensus price target of $130.80, suggesting a potential upside of 50.05%. Given TapImmune’s stronger consensus rating and higher possible upside, equities research analysts plainly believe TapImmune is more favorable than Reata Pharmaceuticals.

Insider & Institutional Ownership

33.6% of TapImmune shares are owned by institutional investors. Comparatively, 54.4% of Reata Pharmaceuticals shares are owned by institutional investors. 23.7% of TapImmune shares are owned by insiders. Comparatively, 34.4% of Reata Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

TapImmune has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.

Valuation & Earnings

This table compares TapImmune and Reata Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TapImmune $210,000.00 1,371.02 -$147.96 million ($1.67) -3.79
Reata Pharmaceuticals $53.59 million 48.89 -$80.55 million ($2.87) -30.37

Reata Pharmaceuticals has higher revenue and earnings than TapImmune. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than TapImmune, indicating that it is currently the more affordable of the two stocks.


This table compares TapImmune and Reata Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TapImmune N/A -113.66% -102.04%
Reata Pharmaceuticals -392.80% N/A -36.58%

TapImmune Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with's FREE daily email newsletter.